Trendlines Group (TRNLY) Stock News

IBI Ag (private) completed the second and final tranche of its $10 million Series A on November 11, 2025, led by Corteva through its Corteva Catalyst platform.

Participants included The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group, Bandera Capital, First Imagine Ventures, and a grant from the Israel Innovation Authority. The funds are intended to accelerate product development and regulatory advancement for IBI Ag's antibody-based (nanobody) bioinsecticide platform, targeting sucking and chewing pests while aiming to reduce ecological impact and preserve beneficial species.

Escala Medical Ltd., a FemTech medical device company specializing in women's health solutions, has secured $4.5 million in funding to accelerate the global expansion of its FDA-approved device for Pelvic Organ Prolapse (POP) treatment.

The funding round includes investment from the EIC Fund, following a €2.5 million grant awarded through the EIC Accelerator program in October 2023, along with participation from private investors in the United States and Israel. The company's flagship Mendit device, which received FDA approval and was commercially launched in 2023, has already been used in hundreds of successful procedures.

The funds will support Escala's commercial operations expansion in the U.S., preparations for European market entry pending CE approval, and international growth through a new distribution agreement covering Southeast Asia. The company currently maintains a direct sales team in the U.S. and is positioned for significant growth in 2025 and beyond.

EcoPhage (TRNLY), a leader in sustainable phage-based biopesticides, has appointed José Alfredo García to its Board of Directors. García brings extensive experience in global agribusiness, having held senior executive roles at Rovensa Group where he focused on biologicals portfolio development and commercial leadership. His prior decade-long experience at FMC Corporation involved leading regulatory, development, marketing, and commercial operations across Mexico, Central America, and the Caribbean. Currently launching Nuvelis, a platform connecting agricultural technologies with distributors, García joins EcoPhage at a crucial time as the company anticipates its first U.S. EPA approval and prepares for commercial rollout. EcoPhage, founded by the Trendlines Group and Bayer, specializes in developing bacteriophage-based solutions for bacterial plant diseases.

Arcuro Medical has received FDA 510(k) clearance for its new SuperBall-RC™ system designed for rotator cuff repair procedures. The technology addresses the significant challenge of rotator cuff re-tear rates, which affect 20%-40% of patients over 50 years old. The system builds upon Arcuro's established SuperBall platform, which has been successfully used in over 5,000 meniscus repairs.

The device aims to simplify the fixation of rotator cuff augmentation grafts, offering surgeons an improved solution for enhanced healing outcomes. Following this regulatory milestone, Arcuro plans a user release in Q2 2025, with a full market launch scheduled for the second half of 2025 - ahead of their original timeline due to expedited FDA clearance.

Limaca Medical has launched its Precision-GI™ endoscopic automated motorized EUS biopsy device in the US market, supported by clinical trials, FDA clearance, and CMS Transitional Pass-Through (TPT) Payment award. The device is designed to obtain improved biopsy results for suspected cancers in the GI tract and adjacent organs.

A clinical trial with 40 patients at IECED Medical Center demonstrated outstanding results, showing Precision-GI's ability to provide consistent, high-quality biopsy samples with excellent tissue quality and procedural efficiency. The device's motorized, automated, rotating cutting mechanism enables superior tissue acquisition with less blood content in a single pass.

The company is initially focusing sales in the New York/New Jersey Metro area, with cases already completed at three NY metro medical centers. The TPT designation reimbursement status is facilitating broader hospital adoption with financial support.

IBI Ag has secured $6.1 million in the first tranche of its Series A funding round, led by Corteva through its Corteva Catalyst platform. Other participants include The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group, along with a grant from the Israel Innovation Authority.

The company is developing bio-insecticides using single domain antibody technology, adapted from pharmaceutical applications for agricultural use. Their products target both sucking and chewing insects while maintaining a low ecological footprint and minimal impact on non-targeted organisms. The technology focuses initially on high-value crops with plans to expand to row crop solutions.

Varana Capital has led the initial closing of Arcuro Medical's Series A financing round, with participation from Trendlines and Consensus Business Group. The funding will support Arcuro's growth and innovation in the medical device industry, with the Series A remaining open for additional investment.

Arcuro Medical achieved several key milestones in 2024, including establishing a new U.S. organization, expanding distribution partnerships, submitting a 510(k) for a new product line, and surpassing 5,000 global SuperBall cases. The company is positioned for significant growth in 2025 with an enhanced product portfolio and expanded market reach.

The company will present at the MSK Innovations Pitch Event on January 8, 2025, providing investors and stakeholders an opportunity to learn more about their vision and advancements.

Limaca Medical's Precision-GI™ endoscopic biopsy device has been granted transitional pass-through (TPT) payment by CMS, effective January 1, 2025, for up to three years. The device, which received FDA Breakthrough Device Designation in 2022 and FDA clearance in August 2023, is designed to improve biopsy results for gastrointestinal cancers. The motorized, automated rotating cutting mechanism enables superior tissue acquisition with less blood content in a single pass, enhancing diagnostic efficiency. The TPT program will support broader patient access by providing additional payments to hospitals to cover adoption costs. The device began its U.S. market entry in September 2024.

ElastiMed has appointed Dr. Amir Belson to its Board of Directors. Dr. Belson brings extensive experience in the medical device industry, having founded several successful companies including Neoguide Systems (acquired by Intuitive Surgical), Vascular Pathways (acquired by C.R. Bard), and Zipline Medical (acquired by Stryker). The appointment comes as ElastiMed prepares to bring its innovative compression therapy device to market. The company focuses on developing wearable medical devices for lymphatic and venous disease patients.